Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched its updated t:slim X2 insulin pump software with the Dexcom (Nasdaq:DXCM) G7.

Integration makes Tandem the first to offer automated insulin delivery with the latest-generation Dexcom continuous glucose monitor (CGM).

The FDA cleared the next-generation Dexcom G7 in December 2022. By February of this year, the company began the U.S. launch of the G7.

However, integration with automated insulin delivery partners, like Tandem, Insulet and Beta Bionics, took a little longer.

Dexcom EVP and COO Jake Leach told Drug Delivery Business News in October that the company anticipated a G7-t:slim X2 launch by the end of the calendar year.

“The Dexcom G7 and t:slim X2 insulin pump integration is the culmination of years of partnership and a shared commitment to improve the lives of people with diabetes,” Leach said in a news release out today. “We’re excited to bring our newest technology to Tandem users so they can experience the benefits of the smallest, most accurate, easy-to-use CGM connected to AID systems.”

Tandem plans to email instructions to all in-warranty t:slim X2 users in the U.S. to offer the new feature free of charge via a remote software update. The company said it has already begun shipping t:slim X2 pumps pre-loaded with the updated software to new customers.

“With this launch we are offering more than 300,000 current t:slim X2 users the ability to integrate with Dexcom’s most advanced CGM technology, demonstrating our commitment to continued leadership in advancing AID systems,” said John Sheridan, president and CEO of Tandem Diabetes Care. “As we celebrate our 10-year partnership with Dexcom, we remain committed to sustaining our rapid pace of innovation to further our mission of helping improve the lives of people with diabetes.”

More about the Dexcom G7 and its integration with Tandem technology

The G7 CGM features a 60% size reduction from the previous generation, the G6. It offers a 30-minute warmup period (down from waiting two hours for glucose readings to begin in the past).

G7 provides more information in one place with personalized insights, extended-wear design and more. It features a simple wear experience, starting with unscrewing a cap. The user then puts the sensor on their body and pushes a button. The device is then turned on and can be paired with a smartphone.

With the integration of G7, Tandem pump users can now spend more time in closed-loop thanks to minimal wait time between sensor sessions. Users can still use the G6 if they prefer it, allowing for more choice in diabetes management.

New results from the COMISAIR seven-year follow-up CGM study further solidify Dexcom’s role in automated insulin delivery. Data showed significant and continued HbA1c reduction and a lowered risk of the development or progression of diabetic retinopathy associated with the use of real-time CGM by people with Type 1 diabetes.

Further data showed substantial reductions in HbA1c with the pairing of Dexcom CGM and the Tandem t:slim X2 with Control-IQ.

“There’s a reason Dexcom is the undisputed leader in CGM connectivity and the clear choice for AID systems,” Leach said. “We pioneered industry-leading CGM connectivity more than a decade ago and are the only CGM company to have safely powered AID systems for more than 1 million patient-years of cumulative use. The clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are proven only when the system is connected to Dexcom CGM technology.”